Please login (Members) to view content or
(Nonmembers) this article.
Average: 5 (2 votes)

Radiodermatitis: Clinical Summary of the ONS Guidelines™ for Cancer Treatment–Related Radiodermatitis

Chelsea Backler
Susan D. Bruce
Lauren Suarez
Pamela K. Ginex
CJON 2020, 24(6), 681-684 DOI: 10.1188/20.CJON.681-684

Approximately 50%–70% of patients with cancer will receive radiation therapy. Radiodermatitis is one of the most common side effects of radiation therapy, with as many as 95% of patients experiencing some degree of skin change. Radiodermatitis can cause pain, itching, and burning and potentially has a significant impact on a patient’s quality of life. If radiodermatitis becomes severe, it can cause treatment interruption. The prevalence of radiodermatitis coupled with the effect this side effect can have on quality of life prompts the need for evidence-based recommendations for management.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or